In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Perkin-Elmer/PerSeptive Biosystems: PE expands its "proteomics" technology portfolio by completing proposed $360 mil. PerSeptive buy, a definitive stock-swap deal for which was announced on Aug. 25 ("The Gray Sheet" Sept. 1, 1997, p. 6). The combination will create a fully integrated technology platform in the field of biomedical research and drug discovery, PE claims...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.